9 hours ago
Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released yesterday, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $936.00. The company's shares closed yesterday at $762.73.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Fernandez is a 5-star analyst with an average return of 12.9% and a 59.46% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Cidara Therapeutics, and Verve Therapeutics.
In addition to Guggenheim, Eli Lilly & Co also received a Buy from Leerink Partners's David Risinger in a report issued on June 18. However, on June 5, Erste Group downgraded Eli Lilly & Co (NYSE: LLY) to a Hold.
Based on Eli Lilly & Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $12.73 billion and a net profit of $2.76 billion. In comparison, last year the company earned a revenue of $8.77 billion and had a net profit of $2.24 billion
